Roche to commercialise Hepatitis C drug in China with Ascletis
ZURICH, April 15
ZURICH, April 15 (Reuters) - Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialise its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.
Under the terms of the agreement, Ascletis will fund and be responsible for regulatory affairs and developing and manufacturing danoprevir in greater China, including Taiwan, Hong Kong and Macau.
Ascletis will receive payments upon reaching certain development and commercial milestones from Roche.
Ten million patients are infected annually with Hepatitis-C in China and there are no direct antiviral agents currently marketed to treat the disease, Ascletis said.
(Reporting by Caroline Copley)